Publications by authors named "Andre Vuilliomenet"

Claim this Profile
C
Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II.
Raban V Jeger, Matthias Pfisterer, Deborah R Vogt, Søren Galatius, Ulrik Abildgaard, André Vuilliomenet

PLoS One· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial.
Juan F Iglesias, Olivier Muller, Serge Zaugg, Marco Roffi, David J Kurz, André Vuilliomenet

EuroIntervention· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction.
Thomas Pilgrim, Raffaele Piccolo, Dik Heg, Marco Roffi, David Tüller, André Vuilliomenet

EuroIntervention· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
Victor A Jiménez, Andrés Iñiguez, José A Baz, Mariano Valdés, Alberto Ortiz, André Vuilliomenet

Cardiovasc Revasc Med· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiographic complexity of coronary artery disease according to SYNTAX score and clinical outcomes after revascularisation with newer-generation drug-eluting stents: a substudy of the BIOSCIENCE trial.
Anna Franzone, Masanori Taniwaki, Fabio Rigamonti, Dik Heg, Raffaele Piccolo, Andre Vuilliomenet

EuroIntervention· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction: Insights From the 2-Year Follow-Up of the BIOSCIENCE Trial.
Raffaele Piccolo, Dik Heg, Anna Franzone, Marco Roffi, David Tüller, André Vuilliomenet

JACC Cardiovasc Interv· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
Rainer Zbinden, Raffaele Piccolo, Dik Heg, Marco Roffi, David J Kurz, André Vuilliomenet

J Am Heart Assoc· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial.
Anna Franzone, Thomas Pilgrim, Dik Heg, Marco Roffi, David Tüller, André Vuilliomenet

Circ Cardiovasc Interv· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
Thomas Pilgrim, Dik Heg, Marco Roffi, David Tüller, Olivier Muller, André Vuilliomenet

Lancet· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial.
Thomas Pilgrim, Marco Roffi, David Tüller, Olivier Muller, André Vuilliomenet

Am Heart J· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Micha T Maeder, Peter Rickenbacher, Hans Rickli, Heidi Abbühl, Marc Gutmann, André Vuilliomenet

Eur J Heart Fail· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidisciplinary Assessment to Personalize Length of Stay in Acute Decompensated Heart Failure (OPTIMA II ADHF).
Frank Dusemund, Martin Steiner, Andre Vuilliomenet, Christian Muller, Rita Bossart

J Clin Med Res· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design.
Raban Jeger, Matthias Pfisterer, Hannes Alber, Franz Eberli, Søren Galatius, André Vuilliomenet

Am Heart J· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis